Coala Life Q1 2023 initial take: Solid growth, but cost base remains heavy - Redeye

Redeye comments on Coala Life’s Q1’23 report, in which we note strong growth, a fast ramp-up in active clinics and an average invoice value of USD110 per patient. The cost base remains heavy but with a c18% improvement from last quarter. Following the report, we expect minor adjustments to our forecast and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/902037/coala-life-q1-2023-initial-take-solid-growth-but-cost-base-remains-heavy?utm_source=finwire&utm_medium=RSS